

### เอกสารอ้างอิง: อันตรกิริยาระหว่างสมุนไพรกับยารักษาเบาหวาน

1. แนวทางเวชปฏิบัติสำหรับโรคเบาหวาน 2560 [อินเทอร์เน็ต]. [สืบค้นเมื่อ วันที่ 7 มิ .ย . 2561]; จาก: <https://www.dmthai.org/attachments/article/443/guideline-diabetes-care-2017.pdf>
2. Yeh GY, Eisenberg DM, Kaptchuk TJ, Phillips RS. Systematic review of herbs and dietary supplements for glycemic control in diabetes. *Diabetes Care*. 2003;26(4):1277-94.
3. May M, Schindler C. Clinically and pharmacologically relevant interactions of antidiabetic drugs. *Ther Adv Endocrinol Metab*. 2016;7(2): 69-83.
4. Gupta RC, Chang D, Nammi S, Bensoussan A, Bilinski K, Roufogalis BD. Interactions between antidiabetic drugs and herbs: an overview of mechanisms of action and clinical implications. *Diabetol Metab Syndr*. 2017;9:59.
5. Rehman SU, Choi MS, Choe K, Yoo HH. Interactions between herbs and antidiabetics: an overview of the mechanisms, evidence, importance, and management. *Arch Pharm Res*. 2015;38(7):1281-98.
6. Rai A, Eapen C, Prasanth VG. Interaction of herbs and glibenclamide: a review. *ISRN Pharmacol*. 2012;2012:659478.doi:10.5402/2012/659478.
7. Izzo AA. Herb-drug interactions: an overview of the clinical evidence. *Fundam Clin Pharmacol*. 2005;19(1):1-16.
8. Ondieki G, Nyagblordzro M, Kikete S, Liang R, Wang L, He X. Cytochrome P450 and P-glycoprotein-mediated interactions involving African herbs indicated for common noncommunicable diseases. *Evid Based Complement Alternat Med*. 2017;2017:ArticleID 2582463.
9. Djuv A, Nilsen OG. *Aloe vera* juice: IC<sub>50</sub> and dual mechanistic inhibition of CYP3A4 and CYP2D6. *Phytother Res*. 2012;26:445-51.
10. Anthony JB, Gregory CM. *Pharmacology weekly*. Retrieved June 2014, from <http://www.pharmacologyweekly.com/content/pages/cytochrome-cyp-p450-enzyme-medicationherbs-substrates>.
11. Pan Y, Abd-Rashid BA, Ismail Z, Ismail R, Mak JW, Pook PC, et al. *In vitro* determination of the effect of *Andrographis paniculata* extracts and andrographolide on human hepatic cytochrome P450 activities. *J Nat Med*. 2011;65(3-4):440-7.
12. Yoon SH, Han EJ, Sung JH, Chung SH. Anti-diabetic effects of compound K versus metformin versus compound K-metformin combination therapy in diabetic db/db mice. *Biol Pharm Bull*. 2007;30(11):2196-200.

13. Mohamed A, Shenoy A, Rajan MS, Shabaraya AR. Evaluation of the anti-diabetic activity of glibenclamide in combination with ginger in streptozotocin induced diabetes. *Int J Pharm Chem Biol Sci.* 2013;2(3):1339-44.
14. Chourey S, Narsinghani T, Soni LK. Effect of *Allium sativum* on the pharmacokinetic of metformin in rat plasma: A herb-drug interaction study. *Der Pharma Chemica.* 2011; 3(2):287-91.
15. Tripathi P, Gupta PP, Lal VK. Effect of co-administration of *Allium sativum* extract and metformin on blood glucose of streptozotocin induced diabetic rats. *J Intercult Ethnopharmacol.* 2013;2(2):81-4.
16. Dholi SK, Raparla R. Effect of *Gymnema sylvestre* on the pharmacokinetics and pharmacodynamics of metformin in diabetic rats. *J Pharmacovigilance.* 2013;1:4. doi.10.4172/2329-6887.S1.009.
17. Raja P, Thejaswini JC, Gurupadayya BM, Mruthyunjaya K, Saranya CHL. Evaluation of influence of gymnema tea on antidiabetic activity of metformin in diabetic rats. *Indo Am J Pharm Res.* 2013;3(12):1262-8.
18. Srujan K, Ramakrishna R, Shravan KD. Effect of *Gymnema sylvestre* extract on the pharmacokinetics and pharmacodynamics of oral hypoglycemic drug - metformin in hyperglycemic rats. *J Pharm Res.* 2014;8(4):614-20.
19. Tongia A, Tongia SK, Dave M. Phytochemical determination and extraction of *Momordica charantia* fruit and its hypoglycemic potentiation of oral hypoglycemic drugs in diabetes mellitus (NIDDM). *Indian J Physiol Pharmacol.* 2004;48(2):241-4.
20. Joseph B, Jini D. Antidiabetic effects of *Momordica charantia* (bitter melon) and its medicinal potency. *Asian Pac J Trop Dis.* 2013;3(2):93-102.
21. Tongia A, Tongia SK, Mangala D. Phytochemical determination and extraction of *Momordica charantia* fruit and its hypoglycemic potentiation of oral hypoglycemic drugs in diabetes mellitus (NIDDM). *Indian J Physiol Pharmacol.* 2004;48(2):241-4.
22. Fuangchan A, Seubnukarn T, Jungpattanawadee D, Sonthisombat P, Ingkaninan K, Plianbangchang P, et al. Retrospective study on the use of bitter melon for type 2 diabetes at Dansai Crown Prince Hospital, Thailand. *Srinagarind Med J.* 2009;24(4):332-8.
23. Zhang DW, Fu M, Gao SH, Liu JL. Curcumin and diabetes: a systematic review. *Evid Based Complement Alternat Med.* 2013;2013:636053.

24. Neerati P, Devde R, Gangi AK. Evaluation of the effect of curcumin capsules on glyburide therapy in patients with type-2 diabetes mellitus. *Phytother Res*. 2014;28(12):1796-800.
25. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. *Clin Pharmacokinet*. 2003;42(1):59-98.
26. Sankar D, Ali A, Sambandam G, Rao R. Sesame oil exhibits synergistic effect with anti-diabetic medication in patients with type 2 diabetes mellitus. *Clin Nutr*. 2011;30(3):351-8.
27. Tanaka M, Misawa E, Ito Y, Habara N, Nomaguchi K, Yamada M. Identification of five phytosterols from *Aloe vera* gel as anti-diabetic compounds. *Biol Pharm Bull*. 2006; 29(7):1418-22.
28. Choudhary M, Kochhar A, Sangha J. Hypoglycemic and hypolipidemic effect of *Aloe vera* L. in non-insulin dependent diabetics. *J Food Sci Technol*. 2014;51(1):90-6.
29. Bunyapraphatsara N, Yongchaiyudha S, Rungpitarangsi V, Chochechaijaroenporn O. Antidiabetic activity of *Aloe vera* L. juice II. clinical trial in diabetes mellitus patients in combination with glibenclamide. *Phytomedicine*. 1996;3(3):245-8.
30. Nagulapalli VKC, Swaroop A, Bagchi D, Bishayee A. A small plant with big benefits: fenugreek (*Trigonella foenum-graecum* Linn.) for disease prevention and health promotion. *Mol Nutr Food Res*. 2017;61(6):1-26.
31. Lu FR, Shen L, Qin Y, Gao L, Li H, Dai Y. Clinical observation on *Trigonella foenum-graecum* L. total saponins in combination with sulfonylureas in the treatment of type 2 diabetes mellitus. *Chin J Integr Med*. 2008;14(1):56-60.
32. Henderson L, Yue Y, Bergquist C, Gerden B, Arlett P. St John's wort (*Hypericum perforatum*): drug interactions and clinical outcomes. *Br J Clin Pharmacol*. 2002;54(4):349-56.
33. Xu H, Williams KM, Liauw WS, Murray M, Day RO, McLachlan AJ. Effects of St John's Wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide. *Br J Pharmacol*. 2008;153(7):1579-86.
34. Sistonen J, Fuselli S, Palo JU, Chauhan N, Padh H, Sajantila A. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. *Pharmacogenet Genomics*. 2009;19(2):170-9.
35. Stage TB, Pedersen RS, Damkier P, Christensen MM, Feddersen S, Larsen JT, et al. Intake of St John's Wort improves the glucose tolerance in healthy subjects who ingest metformin compared with metformin alone. *Br J Clin Pharmacol*. 2015;79(2):298-306.

36. Fan L, Zhou G, Guo D, Liu YL, Chen WQ, Liu ZQ, et al. The pregnane X receptor agonist St John's Wort has no effects on the pharmacokinetics and pharmacodynamics of repaglinide. *Clin Pharmacokinet*. 2011;50(9):605-11.
37. Del SDM, Barba de la RAP, Héliès TC, Guéraud F, Nègre SA. *Opuntia* spp.: Characterization and benefits in chronic diseases. *Oxid Med Cell Longev*. 2017;8634249. doi:10.1155/2017/8634249.
38. Guzman-Maldonado SH, Morales-Montelongo AL, Mondragon-Jacobo C, Herrera-Hernandez G, Guevara-Lara F, Reynoso-Camacho R. Physicochemical, nutritional, and functional characterization of fruits xoconostle (*Opuntia matudae*) pears from central-Mexico Region. *J Food Sci*. 2010;75(6):C485–92.
39. Sobieraj DM, Freyer CW. Probable hypoglycemic adverse drug reaction associated with prickly pear cactus, glipizide, and metformin in a patient with type 2 diabetes mellitus. *Ann Pharmacother*. 2010;44(7–8):1334–7.